Literature DB >> 35737088

Clinical significance of signal regulatory protein alpha and T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain expression in undifferentiated pleomorphic sarcoma.

Shin Ishihara1,2, Takeshi Iwasaki1, Kenichi Kohashi1, Kengo Kawaguchi1,2, Yu Toda1, Toshifumi Fujiwara2, Nokitaka Setsu2, Makoto Endo2, Yoshihiro Matsumoto2, Yasuharu Nakashima2, Yoshinao Oda3.   

Abstract

PURPOSE: Undifferentiated pleomorphic sarcoma (UPS) is associated with poor prognosis. Recently, signal regulatory protein alpha (SIRPα), which is the immune checkpoint of macrophages, and T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domains (TIGIT), which is the immune checkpoint of T cells and natural killer cells, have been considered as potential targets for cancer immunotherapy. This study aimed to assess the value of SIRPα and TIGIT as prognostic factors of UPS.
MATERIALS AND METHODS: The cBio Cancer Genomics Portal was used to analyze mRNA expression data of 50 UPS cases in the Cancer Genome Atlas. We retrieved 49 UPS cases and performed immunohistochemistry (IHC) to detect programmed death ligand 1 (PD-L1), SIRPα, CD68, CD163, TIGIT, CD155, and CD8.
RESULTS: SIRPα was positively associated with CD163 (Pearson's r = 0.51, p = 0.0002) as per open access data and IHC of the cohort (p = 0.002), which revealed that SIRPα-positive macrophage infiltration was higher in UPS cells with ≥ 1% PD-L1 expression than that in UPS cells with < 1% PD-L1 expression (p = 0.047). TIGIT was positively correlated with PD-L1 (r = 0.54, p < 0.0001) and CD8A (r = 0.98, p < 0.0001). In 35 of 49 cases, IHC revealed high levels of TIGIT expression on tumor cells. Furthermore, TIGIT expression on tumor cells was negatively correlated with CD155-positive (p = 0.0144) and CD8-positive (p = 0.0487) cell infiltration. Survival analysis showed that the high degree of SIRPα-positive macrophage infiltration was associated with poor overall survival and metastasis (p < 0.0001, p = 0.0006, respectively).
CONCLUSION: SIRPα-positive macrophages infiltrated UPS cells, which predicted poor prognosis. High TIGIT expression on tumor cells was associated with decreased levels of tumor-infiltrating macrophages in UPS.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  PD-L1; Prognosis; SIRPα; TIGIT; Undifferentiated pleomorphic sarcoma

Year:  2022        PMID: 35737088     DOI: 10.1007/s00432-022-04078-y

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  24 in total

Review 1.  Macrophage checkpoint blockade: results from initial clinical trials, binding analyses, and CD47-SIRPα structure-function.

Authors:  AbdelAziz R Jalil; Jason C Andrechak; Dennis E Discher
Journal:  Antib Ther       Date:  2020-04-18

2.  Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma.

Authors:  Mark P Chao; Ash A Alizadeh; Chad Tang; June H Myklebust; Bindu Varghese; Saar Gill; Max Jan; Adriel C Cha; Charles K Chan; Brent T Tan; Christopher Y Park; Feifei Zhao; Holbrook E Kohrt; Raquel Malumbres; Javier Briones; Randy D Gascoyne; Izidore S Lossos; Ronald Levy; Irving L Weissman; Ravindra Majeti
Journal:  Cell       Date:  2010-09-03       Impact factor: 41.582

3.  PD‑L1 and IDO‑1 expression in undifferentiated pleomorphic sarcoma: The associations with tumor infiltrating lymphocytes, dMMR and HLA class I.

Authors:  Shin Ishihara; Yuichi Yamada; Takeshi Iwasaki; Masato Yoshimoto; Yu Toda; Kenichi Kohashi; Hidetaka Yamamoto; Yoshihiro Matsumoto; Yasuharu Nakashima; Yoshinao Oda
Journal:  Oncol Rep       Date:  2020-11-05       Impact factor: 3.906

4.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

5.  Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab.

Authors:  Emily Z Keung; Melissa Burgess; Ruth Salazar; Edwin R Parra; Jaime Rodrigues-Canales; Vanessa Bolejack; Brian A Van Tine; Scott M Schuetze; Steven Attia; Richard F Riedel; James Hu; Scott H Okuno; Dennis A Priebat; Sujana Movva; Lara E Davis; Damon R Reed; Alexandre Reuben; Christina L Roland; Denise Reinke; Alexander J Lazar; Wei-Lien Wang; Jennifer A Wargo; Hussein A Tawbi
Journal:  Clin Cancer Res       Date:  2020-01-03       Impact factor: 12.531

Review 6.  CD155, an onco-immunologic molecule in human tumors.

Authors:  Jian Gao; Qianqian Zheng; Na Xin; Wei Wang; Chenghai Zhao
Journal:  Cancer Sci       Date:  2017-08-18       Impact factor: 6.716

Review 7.  TIGIT in cancer immunotherapy.

Authors:  Joe-Marc Chauvin; Hassane M Zarour
Journal:  J Immunother Cancer       Date:  2020-09       Impact factor: 13.751

8.  Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas.

Authors:  Amanda R Dancsok; Dongxia Gao; Anna F Lee; Sonja Eriksson Steigen; Jean-Yves Blay; David M Thomas; Robert G Maki; Torsten O Nielsen; Elizabeth G Demicco
Journal:  Oncoimmunology       Date:  2020-04-12       Impact factor: 8.110

9.  TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment.

Authors:  Shusuke Kawashima; Takashi Inozume; Masahito Kawazu; Toshihide Ueno; Joji Nagasaki; Etsuko Tanji; Akiko Honobe; Takehiro Ohnuma; Tatsuyoshi Kawamura; Yoshiyasu Umeda; Yasuhiro Nakamura; Tomonori Kawasaki; Yukiko Kiniwa; Osamu Yamasaki; Satoshi Fukushima; Yuzuru Ikehara; Hiroyuki Mano; Yutaka Suzuki; Hiroyoshi Nishikawa; Hiroyuki Matsue; Yosuke Togashi
Journal:  J Immunother Cancer       Date:  2021-11       Impact factor: 12.469

10.  Clinical significance of signal regulatory protein alpha (SIRPα) expression in esophageal squamous cell carcinoma.

Authors:  Naomichi Koga; Qingjiang Hu; Akihiro Sakai; Kazuki Takada; Ryota Nakanishi; Yuichi Hisamatsu; Koji Ando; Yasue Kimura; Eiji Oki; Yoshinao Oda; Masaki Mori
Journal:  Cancer Sci       Date:  2021-05-19       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.